Register for free to join our community of investors and share your ideas. You will also get access to streaming quotes, interactive charts, trades, portfolio, live options flow and more tools.
Register for free to join our community of investors and share your ideas. You will also get access to streaming quotes, interactive charts, trades, portfolio, live options flow and more tools.
New video out from Dr Joey. Historically Dr Joey has been a major proponent of RLFTF. However, RVVTF has gotten his attention, so we may start seeing several new videos dedicated to RVVTF as a viable investment.
New video out from Dr Joey.
Dr Leuppi is a doctor in Switzerland who is currently conducting an 'inhaler' aviptadil trial with 82 patients with study completion date of Dec 2022. https://clinicaltrials.gov/ct2/show/study/NCT04536350
So he is a STRONG proponent of aviptadil !!
I think the requirement for a miracle is a bit of a stretch. But they do need to survive the SEC investigation. They do that, then we should be off to the races. Unfortunately there is radio silence from both sides during such an investigation. So we patiently wait. It adds no value to let oneself experience grief, anxiety or anger over the situation. It is what it is at this point.
Jedi, I agree. QNTA is 'not' out yet indeed! Only fools with their money panic at this point.
TSOI is a long-term play. The smart investors know that, and they are not consumed or deterred wth/by the daily price fluctuations. Let's see where this is at by YEND 2023.
ACER-001 PDUFA Date (1/15/23)
https://relieftherapeutics.com/newsblog-detail/?newsID=2309453
ACER-001 PDUFA Date (1/15/23)
https://relieftherapeutics.com/newsblog-detail/?newsID=2309477
Ben, It's my understanding that mediation failed and RLFTF is taking NRX to court. I believe that the first court appearance (may be remote) for oral arguments is 9/22/22. NRX is objecting to everything (of course). I say..... "Let the Trials Begin"!!!
https://iapps.courts.state.ny.us/webcivil/FCASCaseInfo?parm=Appearance&index=YzFG20%2FFnaJwmtKbZg1r2g%3D%3D&county=FMGsHEpfaF_PLUS_f2ByFKqilYw%3D%3D&civilCaseId=A263w29bFc98YkFsKY8Xqw%3D%3D
I could be mistaken, but I think that the ADR process is a separate process and they are not linked together. I'm not a lawyer though.
I'm sure that they are on a gag order regarding anything related to the investigation (ex: sec reporting). Yes, they clearly do not respect SEC reporting requirements. That's what got them in this mess to begin with. Whether or not they can put the investigation behind them depends on how deep of a whole they dug themselves into.
IMO, all we can do is wait.
My suggestion to them was to HALT spending any money and time on their business, rather put what little resources they have toward getting through the SEC investigation. At this point, they should not be spending money that they don't have unless it is on the investigation. Freezing all other expenditures is mandatory IMO.
I'm not positive about these guys being a success. I just prefer to work off of facts rather than untruths and fabrications.
LMAO UTTER BULLSHIT !!
I've exchanged emails many times.
Try email. They don't have the staff to answer 1,000 phone calls every day.
They do communicate. You just have to ask. Have you inquired yourself?
QNTA insiders have NOT fled the country. All BS!
BenMoseAshwer - To be honest, I'm on a learning curve with this ADR thing myself. What I know I learned from talking to my broker, RLFTF- IR, and OTC Markets. So I'm reluctant to say anything is for sure. I worry that RAM will change the 1 for 150 to 1 for 250 due to the very low PPS.
I purchased my RLFTF shares on the OTC, so I am expecting that I will be forced to pay the $5 per 15,000 to convert, else I won't be able to sell my shares. So I will need to convert my RLFTF shares to RLFTY at some point. Also, some brokers charge an additional fee for trading foreign securities so that fee would be on top of the $5 per 15,000.
RLFTF IR (Michael) told me that there is a probability that ADR Level 3 will occur BEFORE they uplist to the NASDAQ. Which means that RLFTY will be trading on the OTC for a period of time. I hope not.
I personally do not think that there will be a very tight correlation between between price movement of the underlying Swiss shares and the ADR shares. But I could be wrong. It would seem to me that the demand for shares on the Swiss will be influence by those that are able to buy/sell on the Swiss, independent of the demand on the OTC/NASDAQ. Ex: since I don't trade on the Swiss, my demand/supply behavior would not impact the Swiss price (today). So why would that be any different in the future. I just don't fully understand the correlation aspect of it. Possibly RAM has an option to correlate the prices.
OTC 101, for those that need or want a little education.
What is the Expert Market?
excerpt.....
OTC Markets Group currently operates the Expert Market as a distinct market tier for a small number of companies.
For more info....
https://blog.otcmarkets.com/2021/03/25/understanding-the-expert-market/
LOL UTTER BULLSHIT
Quote:
--------------------------------------------------------
IT is GRAY SHEET TRASH aka de-listed from the OTC
--------------------------------------------------------
The expert market is a tier of the OTC. Flat and simple.
Companies quoted on the OTC Markets are divided into four tiers, the OTCQX, the OTCQB, the OTC Pink and the Expert Market.
Jedi...I 100% agree. If investors have specific questions, they should reach out to the company. A long list of questions here will accomplish nothing. That is a futile effort.
QNTA is not yet dead. Until it stops trading on the OTC it still has a viable heart beat. It's simply just all BS for anyone to suggest otherwise.
Enjoy the weekend!
But what's the point of grieving. A long either holds and waits it out to see where the dust settles, or they write it off as a tax loss and assert their time, focus and energy on other stocks that have future merit. That's what successful traders do. We win some, and we lose some in the penny stocks.
The fat lady has not quite yet sung on QNTA yet though. However, there are plenty of other opportunities to keep my attention.... while I wait for QNTA.
shoon... and, your point is?
Yes, most of that is true. However, after RAM performs a forced 1 for 150 ADR conversion....anyone who currently owns shares on the OTC will see their share count drop by a factor of 150, and they will see their share price increase by a factor of 150. That is exactly how an R/S works.
I have been informed that shares purchased on the Swiss (rather than the OTC), will not experience the 1 for 150 conversion. It's the folks who purchased their shares on the OTC that will experience the 1 for 150 conversion. At ADR Level 3, RAM can start dumping / diluting ADRS to raise $ and put downward price pressure on the ADRs. That's the risk that I'm seeing.
Now it is quite possible that I have been misinformed. However that is how it works according to the folks at OTC Markets. I wish it were different!!
ADR Conversion of 1 for 150 (similar to a R/S). After the conversion at todays price the new pps ....... 150 x .035 = $5.25 (give or take some).
Joe..Great article!! Clearly (in my eyes) something was seriously wrong in the design of the NIH study. It will be interesting to see the assessment of that raw data after the unblinding and release of that data.
Therapeutic Solutions International Granted Emergency IND by FDA for Expanded Patient Access to JadiCell™ Universal Donor Stem Cell for COVID-19 ARDS Outside of Ongoing Phase III Clinical Trial
https://finance.yahoo.com/news/therapeutic-solutions-international-granted-emergency-130000290.html
panton... thanks. It's great to see progress on this. Hopefully the FDA will set a new PDUFA date for 2 months out or less. Full FDA approval of ACER-001 should put a little fire under the RLFTF pps.
In July or Aug the NIH should be unblinding and releasing the Aviptadil trial data. I suspect that there will be some very positive information extracted from that trial data which will be leverage by RLFTF for ROW. They don't need FDA approval to take advantage of Aviptadil's benefits for ROW.
Together with other promising drugs in their pipeline, RLFTF has a bright future. The only concern I have at the moment is the ADF conversion that may occur in 2022.
panton, Great news that ACER didn't drop the ball on this. RLFTF needs the revenues!! Where did you read about the 14 days?
yes, it's a mess. There is no doubt about it.
pegs, I'm at a loss at what to suggest. I'm no doctor, but I would be pulling out all of the stops to exercise that 'Right to Try" path. Maybe hire a lawyer who specializes in the medical/therapeutic field to help make that happen. I would just keep fighting though. Never give up.
three... I totally 100% agree. And I've posted to that effect. I'm very disappointed with both managements (RAM and ACER). You would have thought that at least 'one' senior person would have had the foresight to anticipate such an inspection. Clearly, IMO, there is a deep lack of experience in senior mgmt with dealing with the FDA (incompetence). So now we hold our breath in anticipation of another "faux pas" ! Let's hope they get it right this next time.
shoon.. Over the years I've seen many, many scams in penny stocks. They almost always include the R/S (wash, rinse, repeat). And they do not have a real product. QNTA is a couple notches well above that IMO. The SEC investigation has really hammered this puppy though.
Dilution is ALWAYS a key component of a startup company. That's usually their only means of raising capital. To avoid this high risk, investors should stay away from penny stocks and stick with the big boards. Otherwise, this risk is SOP and goes with the territory.
If a shareholder is polite, they will talk to you over the telephone. But what is the point if the SH simply screams at them or lashes out at them. I wouldn't waste my time talking to such a SH either.
If an investor's risk tolerance is very low, they always have the option of selling their shares and taking the tax write-off... which can be spread out over multiple years. This is a viable option to avoid the grief and permit 'moving on' in the trading world. Every investor has to make that decision for themselves.
fdc4, I'm ok with a buyout if that will help push the pps up to a nickel or a dime. I just don't see a buyout happening under the current situation.
Buying them out at this juncture is out of the question. No buyer would touch a penny stock that is deep into an SEC investigation. Especially one that has zero sales and very little infrastructure. The best they can do is FREEZE all operations, and dig their way out of the SEC issues.
QNTA mgmt recently held a conference call, and they DO respond to email inquires. I would not consider that "in hiding". They do have to work through the SEC mess. If they can clear that hurdle (big If), then it's back to business as usual.
The most important thing from my perspective is - we do NOT want a r/s. As the O/S and float grows, the risk of an r/s increases.
So if QNTA mgmt is reading this board --- to stop the cash flow bleeding (salaries, advertising, construction, etc), we suggest that you put your business operations on HOLD until the SEC investigation is behind you. That is how you can weather this storm without hurting the very shareholders who supported you in prior years. Otherwise, resorting to a devastating r/s will seriously damage your credibility BEYOND repair as you seek to attract future (new) shareholders to support your vision and business initiatives. You NEED the shareholders support.
Jedi...excellent post! Very nice overview of the situation. And thank you for all of your DD (reaching out to QNTA insiders and the Conf Call).
Since the CRL sited that there were no other approval requirements, we are hoping that once the FDA inspection is complete that FDA approval will be quickly forthcoming. If the inspection occurs in July or August, I would like to think that the FDA would make a decision by the end of September (or earlier). Only time will tell.
So, we should see ACER resubmit the NDA sometime in July or August. Other than the routine FDA site inspection, no other approval issue was cited in the CRL which should (no guarantee) allow rapid approval from the FDA. IMO - FDA approval of ACER-001 would be positive news for ACER's holding company ----- RLFTF.
Excerpt.....
The FDA did not cite any other approvability issues in the CRL pertaining to the NDA, nor request any additional clinical or pharmacokinetic studies be conducted prior to FDA approval. The FDA did provide one comment in the CRL (identified as “not an approvability issue”) requesting additional existing nonclinical information to be provided in the resubmission of the NDA.
Acer is actively collaborating with its third-party contract packaging manufacturer and cooperating with the FDA to address the FDA’s comments as soon as reasonably possible and currently intends to resubmit the updated NDA for ACER-001 (sodium phenylbutyrate) for oral suspension for the treatment of patients with UCDs in early-to-mid Q3 2022.
https://www.acertx.com/2022/06/21/acer-therapeutics-and-relief-therapeutics-announce-update-on-u-s-fda-review-of-new-drug-application-nda-for-acer-001/
Vanguard Group must be very optimistic about ACER prospects, which could bode well for RLFTF if the cards fall right. ............
A hedge fund recently raised its stake in Acer Therapeutics stock. Vanguard Group Inc. grew its stake in shares of Acer Therapeutics Inc. (NASDAQ:ACER – Get Rating) by 55.5% in the first quarter, according to the company in its most recent Form 13F filing with the SEC. The firm owned 278,215 shares of the biopharmaceutical company’s stock after purchasing an additional 99,335 shares during the quarter.
https://www.etfdailynews.com/2022/07/12/acer-therapeutics-nasdaqacer-shares-pass-below-two-hundred-day-moving-average-of-2-22/
Yes, I can confirm that they DO respond to phone calls and emails. It's false information that they do not respond to SH inquiries.
There has been no change to the status of QNTA recently. This is old news.